Quantum Genomics

Overview
Price performance
Financials
Research
Thematics

Quantum Genomics is a biopharmaceutical company developing firibastat, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment. The Phase IIb study in hypertension was recently very positive and the Phase IIb in heart failure should start in Q219.

Latest Insights

Healthcare |
Flash note

28.10.22

Quantum Genomics — Firibastat misses endpoints in Phase III

Healthcare |
Update

05.10.22

Quantum Genomics — Steady sailing as FRESH readout approaches

Healthcare |
Initiation

30.08.22

Quantum Genomics — A fresh take on cardiovascular medicine

Healthcare |
Update

09.09.21

Quantum Genomics — Phase IIb QUORUM results

Visit Website

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	6.0	30.1	(91.0)
Relative	8.0	27.4	(92.2)
52 week high/low	€4.0/€0.1

Financials

Edison Investment Research is terminating coverage on Quantum Genomics (ALQGC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.